Oral Targeted Therapies and Central Nervous System (CNS) Metastases

Michael P. Gabay, Scott M. Wirth, Joan M. Stachnik, Colleen L. Overley, Katie E. Long, Linda R. Bressler, John L. Villano

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.

Original languageEnglish
Article number283
Pages (from-to)935-952
Number of pages18
JournalCNS Drugs
Issue number11
StatePublished - Nov 2015

Bibliographical note

Publisher Copyright:
© 2015 Springer International Publishing Switzerland.

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Oral Targeted Therapies and Central Nervous System (CNS) Metastases'. Together they form a unique fingerprint.

Cite this